GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tibet Aim Pharm Inc (SZSE:002826) » Definitions » Revenue

Tibet Aim Pharm (SZSE:002826) Revenue : ¥656.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Tibet Aim Pharm Revenue?

Tibet Aim Pharm's revenue for the three months ended in Mar. 2024 was ¥160.4 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥656.0 Mil. Tibet Aim Pharm's Revenue per Share for the three months ended in Mar. 2024 was ¥0.86. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥3.60.

Warning Sign:

Tibet Aim Pharm Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Tibet Aim Pharm was -19.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was 14.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 10 years, Tibet Aim Pharm's highest 3-Year average Revenue per Share Growth Rate was 17.00% per year. The lowest was -2.30% per year. And the median was 6.80% per year.


Tibet Aim Pharm Revenue Historical Data

The historical data trend for Tibet Aim Pharm's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tibet Aim Pharm Revenue Chart

Tibet Aim Pharm Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 488.77 553.26 602.62 725.46 856.73

Tibet Aim Pharm Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.43 205.01 161.87 128.74 160.43

Competitive Comparison of Tibet Aim Pharm's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Aim Pharm's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Aim Pharm's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Aim Pharm's Revenue distribution charts can be found below:

* The bar in red indicates where Tibet Aim Pharm's Revenue falls into.



Tibet Aim Pharm Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥656.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tibet Aim Pharm  (SZSE:002826) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Tibet Aim Pharm Revenue Related Terms

Thank you for viewing the detailed overview of Tibet Aim Pharm's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Tibet Aim Pharm (SZSE:002826) Business Description

Traded in Other Exchanges
N/A
Address
No. 6, Linqionggang Road, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Aim Pharm Inc is the pharmaceutical company based in China. It is mainly engaged in the research and development, production and sales of chemical drugs and proprietary Chinese medicines for common chronic disease such as diabetes and cardiovascular disease as well as medicines for gynecology and obstetrics. The company's products offering includes miglitol tablets, gualoupi injection, nalmefene hydrochloride injection, carbetocin injection; hongjin xiaojie tablets and aceclofenac enteric-coated tablets. The company also expanded its products in the treatment of antibiotic, antiallergic and digestive system.
Executives
Peng Hui Director
Pang Guo Qiang Directors, executives
Li Qian Jin Securities Affairs Representative
Liu Hang Supervisors

Tibet Aim Pharm (SZSE:002826) Headlines

No Headlines